Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to ritlecitinib with or without narrow-band UVB add-on therapy in patients with active nonsegmental vitiligo: results from a phase 2b extension study.
Yamaguchi Y, Peeva E, Adiri R, Ghosh P, Napatalung L, Hamzavi I, Pandya AG, Shore RN, Ezzedine K, Guttman-Yassky E. Yamaguchi Y, et al. Among authors: peeva e. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03381-4. doi: 10.1016/j.jaad.2024.11.064. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709084
A phase 2a trial of brepocitinib for cicatricial alopecia.
David E, Shokrian N, Del Duca E, Meariman M, Dubin C, Hawkins K, Andrews E, Sikand S, Singer G, Oemar B, Estrada Y, Bose S, Pulsinelli J, Mahling P, Da Rosa JC, Ungar B, Peeva E, Guttman-Yassky E. David E, et al. Among authors: peeva e. J Am Acad Dermatol. 2024 Oct 24:S0190-9622(24)03043-3. doi: 10.1016/j.jaad.2024.09.073. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39461505 Free article.
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis.
Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, Mizuashi M, Shapiro J, Peeva E, Banerjee A, Takiya L, Cox LA, Wajsbrot D, Kerkmann U, Law E, Wolk R, Schaefer G. Mesinkovska N, et al. Among authors: peeva e. J Dermatol. 2024 Nov;51(11):1414-1424. doi: 10.1111/1346-8138.17442. Epub 2024 Sep 27. J Dermatol. 2024. PMID: 39328096 Clinical Trial.
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S, Beebe JS, Chindalore V, Guan S, Hassan-Zahraee M, Saxena M, Xi L, Hyde C, Koride S, Levin R, Lubaczewski S, Salganik M, Sloan A, Stevens E, Peeva E, Vincent MS, Martin DA, Chu M. Cohen S, et al. Among authors: peeva e. Arthritis Res Ther. 2024 Jun 6;26(1):117. doi: 10.1186/s13075-024-03337-2. Arthritis Res Ther. 2024. PMID: 38845046 Free PMC article. Clinical Trial.
87 results